Pharmaceutical composition containing 3,4-dihydro-3-oxo-2-quinoxalines, novel such quinoxalines and processes for the production thereof
申请人:ELI LILLY AND COMPANY
公开号:EP0010426A1
公开(公告)日:1980-04-30
A pharmaceutical composition characterized by as active ingredient a 3,4-dihydro-3-oxoquinoxaline of the formula:
wherein R and R4 are individually H, NO2 or CH30; R1 and R2 are individually H, NO2, CH3O or halo such that at least one of R, R1, R2 and R4 is otherthan H, such that if neitherR1 and R2 is NO2 orCH3O, both RR1 and R2 are individually halo and both R and R4 are H, and such that one ofR1 and R2 is CH3O only if one of R, R1, R2 and R4 is NO2; R3 is C1-C4 alkyl, C3-C6 cycloalkyl, C3-C4 alkenyl, H or 2-chloroethyl; and n is 0 or 2, e.g. ethyl 6,7-dibromo- 3,4-dihydro-3-oxo-2- quinoxaline carboxylate, and excipients is useful for suppressing viral infection in mammals. All but one of the quinoxalines disclosed are new. The compounds are prepared by reacting an o-phenyiene diamine with an a-ketodibasic acid. Certain of the compounds are prepared by reacting a 6-nitro-4,5- disubstituted aniline with an alkyl malonyl chloride followed by annelation in the presence of sodium ethoxide and then treatment with phosphorus trichloride.
一种药物组合物,其活性成分为式 3,4-二氢-3-氧代喹喔啉:
其中R和R4分别为H、NO2或CH30;R1和R2分别为H、NO2、CH3O或卤素,这样R、R1、R2和R4中至少有一个不是H,这样如果R1和R2都不是NO2或CH3O,RR1和R2都分别为卤素,R和R4都是H,这样只有当R、R1、R2和R4中的一个是NO2时,R1和R2中的一个才是CH3O;R3 是 C1-C4 烷基、C3-C6 环烷基、C3-C4 烯基、H 或 2-氯乙基;且 n 是 0 或 2,例如例如,6,7-二溴-3,4-二氢-3-氧代-2-喹喔啉羧酸乙酯和辅料可用于抑制哺乳动物的病毒感染。除一种喹喔啉外,所披露的所有喹喔啉都是新化合物。这些化合物是通过邻苯基二胺与 a-酮二元酸反应制备的。某些化合物是通过 6-硝基-4,5-二取代苯胺与烷基丙二酰氯反应,然后在乙醇钠存在下环化,再用三氯化磷处理而制备的。